Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial

समान संसाधन

• Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: Results from 2 randomized controlled trials
  द्वारा: Zhu, Fengcai, और अन्य
  प्रकाशित: (2014)
• Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18–25 years: event‐triggered analysis of a randomized controlled trial
  द्वारा: Zhu, Feng‐cai, और अन्य
  प्रकाशित: (2016)
• Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial
  द्वारा: Hu, Shangying, और अन्य
  प्रकाशित: (2020)
• Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years
  द्वारा: Einstein, Mark H, और अन्य
  प्रकाशित: (2011)
• Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial
  द्वारा: Zhu, Feng‐Cai, और अन्य
  प्रकाशित: (2019)